BMSCs-exo effectively enhanced neurological recovery, minimized infarct size, mitigated BBB leakage, and upregulated the expression of Claudin-5/Occludin/ZO-1 in the MCAO-HT model. The gene discussed is CLDN5; the disease is hematocrit.